Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHEK1 | O14757 | 3/20 | 0.42 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.42 |
| ▸ | PAK1 | Q13153 | 1/20 | 0.42 |
| ▸ | PIK3CA | P42336 | 9/20 | 0.41 |
| ▸ | PIK3CG | P48736 | 9/20 | 0.41 |
| ▸ | SRC | P12931 | 4/20 | 0.41 |
| ▸ | MTOR | P42345 | 5/20 | 0.40 |
| ▸ | PNP | P00491 | 1/20 | 0.40 |
| ▸ | STAT3 | P40763 | 1/20 | 0.40 |
| ▸ | ABL1 | P00519 | 1/20 | 0.39 |
| ▸ | EGFR | P00533 | 1/20 | 0.39 |
| ▸ | ERBB2 | P04626 | 1/20 | 0.39 |
| ▸ | MET | P08581 | 1/20 | 0.39 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.39 |
| ▸ | KIT | P10721 | 1/20 | 0.39 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.39 |
| ▸ | FLT1 | P17948 | 1/20 | 0.39 |
| ▸ | FGFR2 | P21802 | 1/20 | 0.39 |
| ▸ | EPHA2 | P29317 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17186383 | 0.78 | TLR9 (0.41) | CHEK1PDPK1MAPK1PAK1PIK3CA | |
| Hydrochloric Acid SCHEMBL18605998 | 0.77 | TLR9 (0.40) | CHEK1PDPK1MAPK1PAK1PIK3CA | |
| SCHEMBL41788 | 0.71 | PNP (0.50) | PDPK1PNPDPP4 | |
| SCHEMBL10597948 | 0.71 | PNP (0.46) | PDPK1PNPDPP4 | |
| SCHEMBL20579 | 0.70 | DPP4 (0.50) | PDPK1PNPDPP4 | |
| SCHEMBL1843777 | 0.70 | PNP (0.49) | PDPK1PNPDPP4 | |
| SCHEMBL2983851 | 0.70 | PNP (0.49) | PDPK1PNPDPP4 | |
| SCHEMBL20867 | 0.70 | ATAD2 (0.53) | PDPK1MAPK1PNPDPP4 | |
| SCHEMBL8886040 | 0.70 | PNP (0.49) | PDPK1PNPDPP4 | |
| SCHEMBL2051365 | 0.70 | PNP (0.49) | PDPK1PNPDPP4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8076476-B2 | Synthesis of morpholino oligomers using doubly protected guanine morpholino subunits | AVI BIOPHARMA, INC. (US) | 2011-12-13 | — | — | US | disclosed |
| US-8076476-B2 | Synthesis of morpholino oligomers using doubly protected guanine morpholino subunits | AVI BIOPHARMA, INC. (US) | 2011-12-13 | — | — | US | disclosed |
| CN-101861318-A | Method of synthesis of morpholino oligomers | AVI BIOPHARMA INC | 2010-10-13 | — | — | CN | disclosed |
| CN-101861318-A | Method of synthesis of morpholino oligomers | AVI BIOPHARMA INC | 2010-10-13 | — | — | CN | disclosed |
| EP-2207779-A1 | METHOD OF SYNTHESIS OF MORPHOLINO OLIGOMERS | Avi Biopharma, Inc. (US) | 2010-07-21 | — | — | EP | disclosed |
| EP-2207779-A1 | METHOD OF SYNTHESIS OF MORPHOLINO OLIGOMERS | Avi Biopharma, Inc. (US) | 2010-07-21 | — | — | EP | disclosed |
| WO-2009064471-A1 | METHOD OF SYNTHESIS OF MORPHOLINO OLIGOMERS | AVI BIOPHARMA, INC. (US) | 2009-05-22 | — | — | WO | disclosed |
| WO-2009064471-A1 | METHOD OF SYNTHESIS OF MORPHOLINO OLIGOMERS | AVI BIOPHARMA, INC. (US) | 2009-05-22 | — | — | WO | disclosed |
| US-20090131624-A1 | SYNTHESIS OF MORPHOLINO OLIGOMERS USING DOUBLY PROTECTED GUANINE MORPHOLINO SUBUNITS | AVI BIOPHARMA, INC. (US) | 2009-05-21 | — | — | US | disclosed |
| US-20090131624-A1 | SYNTHESIS OF MORPHOLINO OLIGOMERS USING DOUBLY PROTECTED GUANINE MORPHOLINO SUBUNITS | AVI BIOPHARMA, INC. (US) | 2009-05-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090131624-A1 | SYNTHESIS OF MORPHOLINO OLIGOMERS USING DOUBLY PROTECTED GUANINE MORPHOLINO SUBUNITS | RNMT, O60361, PAM | CHEK1 1600/4885PDPK1 3101/4885MAPK1 2666/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.